Cognitive Pharma

Funding:
Basic research underlying the RBDD technology was sponsored by grants, primarily to the University of Toledo, from pharmaceutical companies, the NIH, and a private foundation. Total expenditures on discovery and development thus far are in excess of $2.5 million. An additional $2.5 million will be required to complete pre-clinical toxicology studies and the manufacturing of CDD-0102, supporting an IND in 2005. The management team believes that the project has the potential for significant return on investment within a reasonable time frame.